Parkinsonism — Reduced Rigidity, Improved Walking and Clearer Speech

Franco Bonifazi, an 81-year-old man from Italy, was diagnosed with parkinsonism. By early 2025, his condition was associated with pronounced motor rigidity, balance instability, reduced mobility, and emerging cognitive decline. These symptoms significantly affected daily functioning, gait safety, and overall independence.

• •Placenta-derived mesenchymal stem cells (MSCs) and MSC-derived exosomes
• •T-regulatory cells derived from cord blood
• •Combined intravenous and intranasal administration over two treatment days
• •Two sessions of Electro-Neuro Therapy (ENT)
• •Personalised exercise programme supervised by a rehabilitation specialist
• •Second treatment cycle (May 2025) with intrathecal administration and adjusted cell dose

• •Noticeably clearer, faster, and more coherent speech
• •Reduced motor rigidity and increased walking capacity
• •Sustained improvements in motor and cognitive function
• •Enhanced responsiveness and cognitive clarity
• •Ongoing rehabilitation refined with emphasis on gait control, postural stability, and fall prevention

Franco remains under ongoing medical observation. Functional improvements have been sustained across both treatment cycles, and his rehabilitation plan continues to be adjusted in line with clinical dynamics and daily performance. Consideration of further treatment cycles remains dependent on neurological evolution and family-defined goals.

This clinical case demonstrates how a multimodal, personalised regenerative medicine approach — integrated with neurostimulation and structured rehabilitation — may support motor and cognitive function in patients with parkinsonism. At BioCells Medical, each programme is individually designed and continuously adapted, with close medical oversight throughout the treatment and follow-up phases.